Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Data Presentation: Crinetics will showcase six abstracts at the 2026 Endocrine Society Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which is expected to boost market confidence and drive sales growth.
- New Drug Research Progress: Full Phase 2 study results for atumelnant will be presented, demonstrating its effectiveness in congenital adrenal hyperplasia, potentially introducing new treatment options in this field and enhancing Crinetics' competitive edge in endocrine disease management.
- Diverse Presentation Formats: Crinetics will conduct oral reports and poster presentations covering the long-term safety and efficacy of PALSONIFY in combination with cabergoline, as well as its real-world application in managing acromegaly, further solidifying its market position.
- Patient Engagement Activity: Crinetics will host a product theater on June 15, inviting patients to share their experiences with PALSONIFY, aiming to enhance interaction with healthcare professionals through patient stories, thereby increasing brand awareness and patient loyalty.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRNX
Wall Street analysts forecast CRNX stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.550
Low
67.00
Averages
89.40
High
105.00
Current: 35.550
Low
67.00
Averages
89.40
High
105.00
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
- Clinical Data Showcase: Crinetics will present six abstracts at the 2026 ENDO Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which could enhance market recognition and drive sales growth.
- Rich Research Findings: The studies on PALSONIFY include results from open-label extension studies lasting up to two years, demonstrating its effectiveness in controlling IGF-1 levels, potentially providing patients with optimized treatment options and enhancing the company's competitiveness in the endocrine disease sector.
- Atumelnant Progress: Crinetics will also showcase full Phase 2 study data for atumelnant in congenital adrenal hyperplasia, indicating its potential to lower glucocorticoid doses, which may offer new solutions for treating ACTH-dependent Cushing's syndrome.
- Product Promotion Event: Crinetics will host a product theater on June 15 titled “Advancing Acromegaly Management,” which aims to enhance PALSONIFY's market awareness by bridging clinical evidence with the patient journey, thereby improving patient treatment experiences.
See More
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
- Clinical Data Presentation: Crinetics will showcase six abstracts at the 2026 Endocrine Society Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which is expected to boost market confidence and drive sales growth.
- New Drug Research Progress: Full Phase 2 study results for atumelnant will be presented, demonstrating its effectiveness in congenital adrenal hyperplasia, potentially introducing new treatment options in this field and enhancing Crinetics' competitive edge in endocrine disease management.
- Diverse Presentation Formats: Crinetics will conduct oral reports and poster presentations covering the long-term safety and efficacy of PALSONIFY in combination with cabergoline, as well as its real-world application in managing acromegaly, further solidifying its market position.
- Patient Engagement Activity: Crinetics will host a product theater on June 15, inviting patients to share their experiences with PALSONIFY, aiming to enhance interaction with healthcare professionals through patient stories, thereby increasing brand awareness and patient loyalty.
See More
ADAR1 Capital Increases Stake in Crinetics Pharmaceuticals
- Share Increase: ADAR1 Capital Management disclosed a purchase of 829,963 shares of Crinetics Pharmaceuticals in Q1 2026, with an estimated trade value of $37.07 million, indicating strong confidence in the company.
- Stake Growth: Following this acquisition, ADAR1's stake in Crinetics now stands at 2.44%, highlighting its significance within the fund's asset management strategy.
- Financial Performance: The quarter-end value of Crinetics increased by $26.98 million due to both the share addition and price changes, despite the company facing a quarterly cash burn of approximately $150 million for R&D and commercialization.
- Market Outlook: Crinetics recently launched its first commercial drug, Palsonify, and while Q1 revenue exceeded expectations, the stock price still fell, reflecting market concerns regarding its future profitability.
See More
Crinetics Pharmaceuticals Q1 2026 Earnings Call Highlights
- Patient Enrollment Surge: Crinetics reported 232 new patient enrollments in Q1 2026, driving net product revenue to $10.3 million, indicating increasing market acceptance of Palsonify, which is on track to become the preferred treatment for acromegaly.
- International Regulatory Progress: The company received MAA approval from the European Commission and submitted applications in Japan and Brazil, demonstrating a strategic push for international market expansion that is expected to lay the groundwork for future revenue growth.
- Reimbursement Coverage Improvement: Approximately 70% of patients were reimbursed by the end of Q1, with a goal to exceed 75% coverage by Q3 2026, which will enhance market competitiveness and increase patient adoption.
- Stable Financial Outlook: Despite R&D expenses reaching $100.1 million in Q1, the company projects that its existing cash and investments will fund operations into 2030, reflecting financial health and ongoing investment capability.
See More
Crinetics Pharmaceuticals: Stock Potential Analysis
- Investment Return Potential: Crinetics Pharmaceuticals (NASDAQ:CRNX) first appeared in Farallon Capital's 13F portfolio in Q3 2018 with over 141,000 shares, indicating early confidence in the investment.
- Holding Dynamics: By early 2019, the fund completely sold off its stake, but reopened a position in Q3 2023, with the latest disclosure showing nearly 500,000 shares in Q2 2024, reflecting sustained interest in the company.
- Optimistic Market Outlook: Crinetics' PALSONIFY received European Commission approval, becoming the only once-daily oral treatment on the market, with projected revenues of $62 million in 2026, significantly exceeding original consensus estimates, indicating rapid market acceptance of its product.
- Increased Hedge Fund Confidence: Early data shows a 5% adoption rate for PALSONIFY within months of launch, suggesting that hedge funds are optimistic about Crinetics' future growth, which could drive stock price increases.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
- Clinical Data Showcase: Crinetics will present six abstracts at the 2026 ENDO Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which could enhance market recognition and drive sales growth.
- Rich Research Findings: The studies on PALSONIFY include results from open-label extension studies lasting up to two years, demonstrating its effectiveness in controlling IGF-1 levels, potentially providing patients with optimized treatment options and enhancing the company's competitiveness in the endocrine disease sector.
- Atumelnant Progress: Crinetics will also showcase full Phase 2 study data for atumelnant in congenital adrenal hyperplasia, indicating its potential to lower glucocorticoid doses, which may offer new solutions for treating ACTH-dependent Cushing's syndrome.
- Product Promotion Event: Crinetics will host a product theater on June 15 titled “Advancing Acromegaly Management,” which aims to enhance PALSONIFY's market awareness by bridging clinical evidence with the patient journey, thereby improving patient treatment experiences.
See More
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
- Clinical Data Presentation: Crinetics will showcase six abstracts at the 2026 Endocrine Society Annual Meeting, including long-term safety and efficacy data for PALSONIFY™, emphasizing its best-in-class potential in treating acromegaly, which is expected to boost market confidence and drive sales growth.
- New Drug Research Progress: Full Phase 2 study results for atumelnant will be presented, demonstrating its effectiveness in congenital adrenal hyperplasia, potentially introducing new treatment options in this field and enhancing Crinetics' competitive edge in endocrine disease management.
- Diverse Presentation Formats: Crinetics will conduct oral reports and poster presentations covering the long-term safety and efficacy of PALSONIFY in combination with cabergoline, as well as its real-world application in managing acromegaly, further solidifying its market position.
- Patient Engagement Activity: Crinetics will host a product theater on June 15, inviting patients to share their experiences with PALSONIFY, aiming to enhance interaction with healthcare professionals through patient stories, thereby increasing brand awareness and patient loyalty.
See More
ADAR1 Capital Increases Stake in Crinetics Pharmaceuticals
- Share Increase: ADAR1 Capital Management disclosed a purchase of 829,963 shares of Crinetics Pharmaceuticals in Q1 2026, with an estimated trade value of $37.07 million, indicating strong confidence in the company.
- Stake Growth: Following this acquisition, ADAR1's stake in Crinetics now stands at 2.44%, highlighting its significance within the fund's asset management strategy.
- Financial Performance: The quarter-end value of Crinetics increased by $26.98 million due to both the share addition and price changes, despite the company facing a quarterly cash burn of approximately $150 million for R&D and commercialization.
- Market Outlook: Crinetics recently launched its first commercial drug, Palsonify, and while Q1 revenue exceeded expectations, the stock price still fell, reflecting market concerns regarding its future profitability.
See More
Crinetics Pharmaceuticals Q1 2026 Earnings Call Highlights
- Patient Enrollment Surge: Crinetics reported 232 new patient enrollments in Q1 2026, driving net product revenue to $10.3 million, indicating increasing market acceptance of Palsonify, which is on track to become the preferred treatment for acromegaly.
- International Regulatory Progress: The company received MAA approval from the European Commission and submitted applications in Japan and Brazil, demonstrating a strategic push for international market expansion that is expected to lay the groundwork for future revenue growth.
- Reimbursement Coverage Improvement: Approximately 70% of patients were reimbursed by the end of Q1, with a goal to exceed 75% coverage by Q3 2026, which will enhance market competitiveness and increase patient adoption.
- Stable Financial Outlook: Despite R&D expenses reaching $100.1 million in Q1, the company projects that its existing cash and investments will fund operations into 2030, reflecting financial health and ongoing investment capability.
See More
Crinetics Pharmaceuticals: Stock Potential Analysis
- Investment Return Potential: Crinetics Pharmaceuticals (NASDAQ:CRNX) first appeared in Farallon Capital's 13F portfolio in Q3 2018 with over 141,000 shares, indicating early confidence in the investment.
- Holding Dynamics: By early 2019, the fund completely sold off its stake, but reopened a position in Q3 2023, with the latest disclosure showing nearly 500,000 shares in Q2 2024, reflecting sustained interest in the company.
- Optimistic Market Outlook: Crinetics' PALSONIFY received European Commission approval, becoming the only once-daily oral treatment on the market, with projected revenues of $62 million in 2026, significantly exceeding original consensus estimates, indicating rapid market acceptance of its product.
- Increased Hedge Fund Confidence: Early data shows a 5% adoption rate for PALSONIFY within months of launch, suggesting that hedge funds are optimistic about Crinetics' future growth, which could drive stock price increases.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
